The White House is proposing cutting the Public Health Service Commissioner Corps, which is deployed during disasters and disease outbreaks, by nearly 40%; payments made by opioid manufacturers to physicians have decreased as public attention to the opioid epidemic grows; mistrust of drugs and doctors may partly explain why black patients are less likely than white patients to take recommended statins.
The Public Health Service Commissioner Corps currently has 6500 public health professionals who are deployed during disasters and disease outbreaks, but the White House is proposing cutting that force by nearly 40%. The Washington Post reported that the administration wants “a leaner and more efficient organization” made up of no more than 4000 officers. During hurricanes Harvey, Irma, and Maria, more than 1460 officers were sent to respond and nearly 300 went to Liberia during the Ebola epidemic.
Payments made by opioid manufacturers to physicians for speaking, consulting, meals, and travel related to opioids have decreased as public attention to the opioid epidemic grows. In 2016, drug makers paid doctors $15.8 million, which was down from 23.7 million in 2015, according to a report from NPR and ProPublica. Payments for Subsys, a fentanyl spray from Insys, and Hysingla ER, an extended-release version of Purdue Pharma’s hydrocodone, represented the largest drops in spending.
A new study found that mistrust of drugs and doctors may partly explain why black patients are less likely than white patients to take recommended statins. According to Reuters, 82% of black patients said they trusted their physician compared with 94% of white patients. In addition, far fewer black patients thought statins were safe (36% vs 57%) and slightly fewer thought they were effective (70% vs 74%). In general, both groups were receiving doses that were too low: 33% of black patients and 44% of white patients were given doses high enough to comply with guidelines.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Ravulizumab-cwvz for Rare Autoimmune Disease
March 28th 2024Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.
Read More
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More